A number of other equities analysts also recently commented on the company. ValuEngine downgraded OraSure Technologies from a buy rating to a hold rating in a report on Friday, May 1st. Lake Street Capital assumed coverage on OraSure Technologies in a report on Thursday, June 25th. They set a buy rating and a $19.00 price target on the stock. Stephens assumed coverage on OraSure Technologies in a report on Tuesday, April 21st. They set an equal weight rating and a $14.00 price target on the stock. Finally, Zacks Investment Research upgraded OraSure Technologies from a hold rating to a strong-buy rating and set a $18.00 price target on the stock in a report on Wednesday, May 6th. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $14.75.
Shares of OraSure Technologies stock opened at $11.63 on Friday. OraSure Technologies has a 1 year low of $5.23 and a 1 year high of $18.27. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.62 and a current ratio of 8.48. The company has a market capitalization of $674.66 million, a P/E ratio of 58.15 and a beta of 0.51. The company’s fifty day moving average is $12.60 and its two-hundred day moving average is $9.86.
Several institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp boosted its position in shares of OraSure Technologies by 2.7% in the first quarter. State Street Corp now owns 2,642,713 shares of the medical instruments supplier’s stock valued at $28,436,000 after acquiring an additional 69,817 shares during the period. Royal Bank of Canada boosted its position in shares of OraSure Technologies by 137.6% in the first quarter. Royal Bank of Canada now owns 39,161 shares of the medical instruments supplier’s stock valued at $421,000 after acquiring an additional 22,679 shares during the period. Fred Alger Management LLC bought a new stake in shares of OraSure Technologies in the first quarter valued at approximately $726,000. Advisor Group Holdings Inc. bought a new stake in shares of OraSure Technologies in the first quarter valued at approximately $110,000. Finally, AQR Capital Management LLC boosted its position in shares of OraSure Technologies by 5.9% in the first quarter. AQR Capital Management LLC now owns 249,424 shares of the medical instruments supplier’s stock valued at $2,684,000 after acquiring an additional 13,981 shares during the period. 90.07% of the stock is owned by institutional investors.
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Featured Story: Green Investing
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.